Can neratinib/neratinib be reimbursed by medical insurance?

Neratinib/Neratinib (Neratinib) is a targeted therapy drug designed for extended adjuvant treatment of HER2-positive breast cancer. In recent years, this drug has been launched in China and has entered the scope of Category B drugs in the National Medical Insurance Catalog. However, its medical insurance reimbursement policy has certain limitations and needs to be analyzed based on the patient's condition, treatment stage and drug indications.

According to the latest information on China's national medical insurance policy, the scope of medical insurance payment for neratinib is mainly limited to patients with early-stage HER2-positive breast cancer, and it can only be used as an intensive adjuvant treatment after completing adjuvant therapy containing trastuzumab. This regulation specifically excludes patients with advanced or metastatic breast cancer from reimbursement eligibility. Even if such patients have been recommended to be used in combination with capecitabine in overseas guidelines, they are not covered by Chinese medical insurance. Therefore, in clinical application, doctors need to fully communicate with patients about medical insurance indication requirements before prescribing, so as to avoid the financial pressure of paying for drugs outside medical insurance during the treatment process.

In terms of price, the original version of neratinib is currently marketed in China in the form of 40mg tablets, with each box containing 180 tablets. Based on a daily dose of 240 mg (i.e. 6 tablets per day), each box of medicine can roughly meet 30 days of treatment needs. The price before medical insurance is around RMB 7,000. The specific price may fluctuate slightly depending on the region, hospital procurement methods and policy adjustments. Even if it is included in the medical insurance catalog, the use of neratinib must still strictly follow the instructions approved by the State Food and Drug Administration and the medical insurance restrictions.

During use, if the patient's condition exceeds the medical insurance indications, such as for HER2-positive advanced breast cancer or after trastuzumab treatment failure, the patient must pay the full amount out of pocket, or choose overseas generic drugs as a lower-priced alternative.

Reference materials:https://en.wikipedia.org/wiki/Neratinib